Default company panoramic image

Promise Health, SPC

Promise Health is developing a disruptive medical device to transdermally and bloodlessly detect, and rapidly quantify, all malaria species.

  • Stage Product In Development
  • Industry Medical Devices and Equipment
  • Location Seattle, WA, USA
  • Currency USD
  • Founded July 2013
  • Employees 0
  • Website

Company Summary

Promise Health is a for-profit corporation with a social purpose to promote global malaria control and eradication by delivering to the market quality medical devices capable of noninvasive, transdermal detection and measurement of malaria infection and other tropical diseases. The MalariSense device will be customized to meet global user needs, changing the paradigms of malaria screening, case detection and population monitoring.


  • Default avatar
    Michael Wandell
    President & CEO

    Dr. Wandell is an Entrepreneur in Residence (EIR) at Rice University's Houston Area Translational Research Consortium (HATRC), a "think tank" with an outcome-based mission: to bridge the gap between basic research and the health care marketplace. As biomedical executive and clinical pharmacologist, Dr. Wandell has a track record of applying sound judgment grounded in high ethical standards to create regulatory strategies delivering novel medic

  • Default avatar
    Natalie Wright Curley
    General Counsel

    Natalie Wright Curley, J.D. is a registered patent attorney with over 17 years of experience in intellectual property and licensing. She specializes in assisting new and small biotech start ups with university transactions, including licensing, sponsored research and faculty consulting agreements, as well as IP and business strategy. Natalie specialties intellectual property law, university licensing and contracts, faculty consulting agreements,

  • Default avatar
    Dmitri Lapotko
    Head of Science

    Dmitri Lapotko (Rice University): more than 20 years of experience in biomedical nanophotonics. He invented plasmonic nanobubbles and the diagnostic and therapeutic cell level technologies [4,5]. He has more than 50 publications on nanophotonics and nanobubbles and a state of the art lab for in vitro and in vivo photonic research and engineering.

  • Default avatar
    David Sullivan
    Chief Medical Officer

    Dr. David Sullivan (Johns Hopkins Malaria Research Institute) has 20 years of experience in malaria research [1] with his laboratory now with more than a dozen researchers working on all aspects of the malaria lifecycle in relationship to biology, pathogenesis, diagnostics, drugs, immunology, vaccines and epidemiology. He has more than 30 publications on hemozoin and/or malaria diagnostics.


  • Default avatar
    Michael "Mick" Fleming
    Default avatar

Previous Investors

  • Default avatar